Inhibrx Biosciences, Inc.Giá lên
$INBX is giving a GREAT IPO LONG opportunity today
Cập nhật
IPO intraday trading strategy idea
Inhibrx is advancing a pipeline of candidates for the treatment of various rare cancers and AATD.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $26;
take-profit — $46;
stop-loss — $19.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Inhibrx is advancing a pipeline of candidates for the treatment of various rare cancers and AATD.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $26;
take-profit — $46;
stop-loss — $19.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Giao dịch được đóng thủ công
$20,63
More information: fondexx.pro/
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
Bài đăng liên quan
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.